Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.
about
Clinical applications of PD-L1 bioassays for cancer immunotherapy.Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancerImpact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer.Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.Trial watch: Immune checkpoint blockers for cancer therapy.Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.Repurposing tin mesoporphyrin as an immune checkpoint inhibitor shows therapeutic efficacy in preclinical models of cancer.New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms.Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment.Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in ITargeting immune checkpoints in breast cancer: an update of early results.Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
P2860
Q33702815-59EDF3D4-594C-4A5C-85D4-D2ACD69FCB9EQ38670277-A83BFC25-1917-4A71-86AC-A75A0960A5CFQ38704949-82870A48-BFFB-40C4-AA57-69BBB46B3D90Q38751056-4979D450-255D-48E7-B57B-6C2E7A4901EDQ41810793-7623D2C2-4CA0-4F15-981B-9D1350199E38Q47109363-06D5637C-ED66-40C0-B7C1-DD67AEA0A3D3Q47393365-E9B5A620-9B2F-46D0-A9F8-6FC6A0A44D9AQ47395423-2D205499-1A70-4475-B026-24B5933A9198Q50020477-24E06D75-FEBA-4E5D-BD10-614C91E2823CQ52641617-008122AF-7C94-4750-8956-8010CB13BE14Q52725437-3A85D080-E71D-4D45-B58D-252DE1DC9811Q54685474-4ACC2A39-04E6-4B27-991F-AAE7F3A78351Q55182988-980A4D3B-F6F2-4879-85C7-8CC2792D7EB1Q57191726-2D481616-ABD7-449E-95E2-85C02983ED41
P2860
Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor-infiltrating lymphocyte ...... n are linked in breast cancer.
@en
Tumor-infiltrating lymphocyte ...... n are linked in breast cancer.
@nl
type
label
Tumor-infiltrating lymphocyte ...... n are linked in breast cancer.
@en
Tumor-infiltrating lymphocyte ...... n are linked in breast cancer.
@nl
prefLabel
Tumor-infiltrating lymphocyte ...... n are linked in breast cancer.
@en
Tumor-infiltrating lymphocyte ...... n are linked in breast cancer.
@nl
P2093
P2860
P50
P1433
P1476
Tumor-infiltrating lymphocyte ...... on are linked in breast cancer
@en
P2093
Alexandre de Wind
Anais Boisson
Christos Sotiriou
Céline Naveaux
Denis Larsimont
Gert Van den Eynden
Hugues Duvillier
Isabelle Veys
Jean-Nicolas Lodewyckx
John Stagg
P2860
P304
P356
10.1080/2162402X.2016.1257452
P577
2016-12-14T00:00:00Z